oligonucleotide therapy for Huntington’s disease (Exicure/Ipsen)

N/A

Report date: 2025/01/26 16:26:10
NME

Base Information

Drug Nameoligonucleotide therapy for Huntington’s disease (Exicure/Ipsen)
Drug Alias Nameoligonucleotide therapy for Huntington’s disease (Exicure)spherical nucleic acids program (Exicure/Ipsen)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionNeuroprotectants
TargetsUpdating
Therapy Area/IndicationsHuntington Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFrance
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesExicure Inc
China Registration ClassN/A

Develop Information

Active CompaniesExicure IncIpsen SA
Inactive CompaniesN/A
Active IndicationsHuntington Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A